Dr. Emily Taraneh Tamadonfar, MD

Dr. Tamadonfar practices at Keck Hospital of USC in Los Angeles, California, part of University of Southern California.

Dr. Tamadonfar's NPI, 1689105777, was assigned on March 21, 2017. Dr. Tamadonfar graduated from Chicago Medical School at Rosalind Franklin University of Medicine and Science in 2017. Dr. Tamadonfar holds California license A171184.

Dr. Tamadonfar's primary practice is Keck Hospital of USC, at 1500 San Pablo Street, Los Angeles, CA 90033 in Los Angeles County. The practice phone is (323) 442-8656.

Dr. Tamadonfar's primary practice is Keck Hospital of USC in Los Angeles, California, part of University of Southern California. Dr. Tamadonfar is also affiliated with Eisenhower Health. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. Tamadonfar to 2 more hospitals, 1 group practice or clinic, 1 other site and 1 urgent care center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tamadonfar practices, 7 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Tamadonfar's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Tamadonfar is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Tamadonfar's licenses on file in 2 states: California and Iowa.

Dmand AI lists essential tremor, mobility impairment, neuropathy, non-alzheimer's dementia (chronic), parkinson's disease and restless legs syndrome among the conditions Dr. Tamadonfar treats.

CMS data shows 491 Medicare services from Dr. Tamadonfar across 5 procedure codes in 2024, for 219 Medicare patients. Medicare paid $43,442 for them.

CMS counts 219 Medicare patients who saw Dr. Tamadonfar in 2024. The largest group is 75 to 84, with 86 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 34% are also on Medicaid. Their average risk score is 1.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tamadonfar's median patient age at 73, with 48% women.

In 2024, Dr. Tamadonfar wrote 713 Medicare Part D claims for 148 patients. 86% of them were for generic drugs. CMS names the drug for 571 of them, across 14 drugs with 11 or more claims each, at $67,635 in total drug cost. In 2023, CMS named 798 claims across 20 drugs.

Dr. Tamadonfar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tamadonfar as offering telehealth. CMS counts 12 procedures of skin biopsy by Dr. Tamadonfar, more than 60% of the clinicians it reports for that procedure.

Dmand AI links 1 paper to Dr. Tamadonfar in 2020. Dr. Tamadonfar's most frequent co-authors are Sudeepta Dandapat, MD and Colin P. Derdeyn, MD.

CMS Open Payments shows 30 general payments to Dr. Tamadonfar from 7 drug and device companies from 2021 to 2025. Grants make up the largest share, 87% of the total. Boston Scientific Corporation paid the most, $11,175.

Dr. Tamadonfar graduated from Chicago Medical School at Rosalind Franklin University of Medicine and Science in 2017.

Dr. Tamadonfar is in network with 6 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.